Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...

In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and ...

(RTTNews) - Quest Diagnostics (DGX), Wednesday announced the launch of a new blood test designed to confirm amyloid brain pathology due to Alzheimer's disease (AD) in patients with mild cognitive ...

SECAUCUS, N.J., Oct. 27, 2025 /PRNewswire/ -- Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients, supporting ...

Quest Diagnostics may be the preferred lab your health insurance, doctors, or specialists use for blood work or other samples. We’re reviewing its sub-brand Quest Health, from which you can order your ...

Quest Diagnostics Incorporated (NYSE:DGX) is one of the 7 most undervalued pot stocks to buy according to analysts. On June 10, the company said it is developing a Multi-Cancer Stratification (MCaST) ...

SECAUCUS, N.J., April 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of ...